Morgan Stanley raised the firm’s price target on Gilead (GILD) to $175 from $171 and keeps an Overweight rating on the shares. The firm adjusted models among its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting from the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- MacroGenics upgraded to Buy at B. Riley after deal for Tubulus
- Tempus AI announce strategic collaboration with Gilead
- Kymera Therapeutics announces Gilead option exercise to license KT-200
- Gilead price target raised to $155 from $152 at Truist
- Balancing Strategic Oncology Expansion and Execution Risk: Why Gilead’s Tubulis Deal Supports a Hold Rating